# Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

> **NCT02947165** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Hepatocellular Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Renal Cancer

## Interventions

- **DRUG:** NIS793
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02947165
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-25
- **Primary completion:** 2021-06-18
- **Final completion:** 2021-06-18
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947165, "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02947165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*